News Release

Landiolol and organ failure in patients with septic shock

JAMA

Peer-Reviewed Publication

JAMA Network

About The Study: The results of this randomized clinical trial involving 126 patients do not support the use of the very short-acting beta-blocker landiolol for managing patients with tachycardia treated with norepinephrine for established septic shock. 

Authors: Tony Whitehouse, M.D., of Queen Elizabeth Hospital in Birmingham, United Kingdom, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2023.20134)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the European Society of Intensive Care Medicine Lives 2023 36th Annual Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.20134?guestAccessKey=00587723-286b-48ea-82e4-513001695b9a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102523


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.